Publications by authors named "Jianning Yang"

Claim this Profile
G
Gymconopin C exhibits anti-non-small cell lung cancer effect by regulating miR-6777-5p/ADRB2 pathway to promote mitophagy.
Xue Li, Mingyu Han, Limei Zhang, Xiaofang Xie, Chenying Li, Jianning Yang, Changnian Yang

J Adv Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isocucurbitacin B inhibits gliomas through the promotion of anoikis by targeting caveolin 1.
Mingyu Han, Jianning Yang, Pingting Chen, Sui Li, Hailin Tang

Cancer Lett· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab.
Jianning Yang, Akihiro Yamada, Kohei Shitara, Rui-Hua Xu, David Ilson

Clin Pharmacokinet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Web-Based Video Platforms as Sources of Information on Body Image Dissatisfaction in Adolescents: Content and Quality Analysis of a Cross-Sectional Study.
Li Liu, Jianning Yang, Fengmei Tan, Huan Luo, Yanhua Chen

JMIR Form Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Akihiro Yamada, Jianning Yang, Peter L Bonate, Nakyo Heo, Srinivasu Poondru

Cancer Chemother Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Digital Interventions for Improving Body Dissatisfaction in Children and Emerging Adults: Systematic Review and Meta-Analysis.
Li Liu, Jianning Yang, Fengmei Tan, Xia Yang, Huan Luo

Interact J Med Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.
Akihiro Yamada, Masato Takeuchi, Kanji Komatsu, Peter L Bonate, Srinivasu Poondru, Jianning Yang

Clin Transl Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IQ Survey Results on Current Industry Practices-Part 1: Immunogenicity Risk Assessment.
Christine Grimaldi, Susan Richards, Daniel Baltrukonis, Shelley Sims Belouski, Kelly Coble, Jianning Yang

Clin Pharmacol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IQ Survey Results on Current Industry Practices: Part 2-Quantitative Evaluations of Immunogenicity Assessment.
Susan Richards, Insa Winzenborg, Doreen Luedtke, Tao Niu, Lora Hamuro, Jianning Yang

Clin Pharmacol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, Nageshwar Budha, Ferdous Gheyas, Jianning Yang

Clin Pharmacol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Samuel J Klempner, Keun-Wook Lee, Kohei Shitara, Jean-Phillippe Metges, Sara Lonardi, Jianning Yang

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Jianning Yang

Lancet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Martina Puglisi, L Rhoda Molife, Maja Ja de Jonge, Khurum H Khan, Leni van Doorn, Jianning Yang

Future Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Anthony W Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A Busman, Guinan Lian, Jianning Yang

Cancer Chemother Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Andrew W Roberts, Ranjana H Advani, Brad S Kahl, Daniel Persky, John W Sweetenham, Jianning Yang

Br J Haematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
Gordana Vlahovic, Vassiliki Karantza, Ding Wang, David Cosgrove, Nikita Rudersdorf, Jianning Yang

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
James M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, Alberto J Montero, Catherine Franklin, Jianning Yang

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.
Aksana Kaefer, Jianning Yang, Peter Noertersheuser, Sven Mensing, Rod Humerickhouse

Cancer Chemother Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
Ahmed Hamed Salem, Jianning Yang, Alison Graham, Amita Patnaik, Kyle Holen

Anticancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Baseline drift of electrocardiograph dealt with mathematical morphology filter in real-time].
Xianglin Zhu, Jianning Yang, Ping Tang, Xin Ling

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Determination of the components of bitespiramycin by HPLC].
Ya-Li Yang, Jian-Ning Yang, Min Hu, Chang-Qin Hu

Yao Xue Xue Bao· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis